These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 16882944)

  • 1. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
    Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
    J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design of shepherdin, a novel anticancer agent.
    Plescia J; Salz W; Xia F; Pennati M; Zaffaroni N; Daidone MG; Meli M; Dohi T; Fortugno P; Nefedova Y; Gabrilovich DI; Colombo G; Altieri DC
    Cancer Cell; 2005 May; 7(5):457-68. PubMed ID: 15894266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
    Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
    J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
    Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
    Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
    Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
    Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
    Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting HSP90/Survivin using a cell permeable structure based peptido-mimetic shepherdin in retinoblastoma.
    Venkatesan N; Kanwar JR; Deepa PR; Navaneethakrishnan S; Joseph C; Krishnakumar S
    Chem Biol Interact; 2016 May; 252():141-9. PubMed ID: 27062892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.
    Williams CR; Tabios R; Linehan WM; Neckers L
    J Urol; 2007 Oct; 178(4 Pt 1):1528-32. PubMed ID: 17707057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
    Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.
    Nakashima T; Ishii T; Tagaya H; Seike T; Nakagawa H; Kanda Y; Akinaga S; Soga S; Shiotsu Y
    Clin Cancer Res; 2010 May; 16(10):2792-802. PubMed ID: 20406843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis.
    Fredly H; Ersvær E; Gjertsen BT; Bruserud O
    Oncol Rep; 2011 Jun; 25(6):1549-56. PubMed ID: 21431284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors.
    Dakappagari N; Neely L; Tangri S; Lundgren K; Hipolito L; Estrellado A; Burrows F; Zhang H
    Biomarkers; 2010 Feb; 15(1):31-8. PubMed ID: 19747088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].
    Sun JR; Zhang XH; He ZW; Gu Y; Yu YZ; Fang YM; Lü QH; Dong QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2246-51. PubMed ID: 17064567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antileukemic effect of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypercalcemia.
    Yoon JS; Kim JY; Park HK; Kim ES; Ahn KS; Yoon SS; Cho CG; Kim BK; Lee YY
    Int J Oncol; 2008 Feb; 32(2):387-96. PubMed ID: 18202761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
    Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
    J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy.
    Nieto-Miguel T; Gajate C; González-Camacho F; Mollinedo F
    Oncogene; 2008 Mar; 27(12):1779-87. PubMed ID: 17891170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.